down arrow

Infinity Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45665G3039
USD
0.00
0 (0.00%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

281

Shareholding (Dec 2023)

FII

5.98%

Held by 31 FIIs

DII

80.57%

Held by 17 DIIs

Promoter

0.10%

Who are in the management team of Infinity Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Infinity Pharmaceuticals, Inc. includes Ms. Adelene Perkins as Chairman and CEO, along with Board members Mr. Norman Selby, Dr. Samuel Agresta, and independent directors Mr. David Beier, Dr. Anthony Evnin, and Dr. Richard Gaynor.

As of March 2022, the management team of Infinity Pharmaceuticals, Inc. includes Ms. Adelene Perkins, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the Board of Directors are Mr. Norman Selby, the Lead Independent Director; Dr. Samuel Agresta, a Director; and independent directors Mr. David Beier, Dr. Anthony Evnin, and Dr. Richard Gaynor.

Read More

Is Infinity Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Infinity Pharmaceuticals, Inc. is considered overvalued and has deteriorated from a risky to a non-qualifying investment grade, with negative EV to EBIT and EV to EBITDA ratios, and significant underperformance compared to the S&P 500.

As of 8 July 2024, the valuation grade for Infinity Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. Based on the available metrics, the company appears to be overvalued given its negative EV to EBIT (-0.73), negative EV to EBITDA (-0.74), and an extremely high ROE of 109.47%, which is misleading due to negative capital employed. <BR><BR>In comparison with peers, Avalo Therapeutics, Inc. has a P/E of -2.6865 and an EV to EBITDA of -0.6568, while ABVC BioPharma, Inc. shows a P/E of -20.1140 and an EV to EBITDA of -23.1803, both indicating that Infinity's ratios are not competitive. Furthermore, Infinity's stock has dramatically underperformed against the S&P 500 over the past three years and five years, with returns of -99.99% compared to the S&P 500's 70.41% and 96.61%, respectively, reinforcing the notion that the stock is currently overvalued.

Read More

Is Infinity Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of November 29, 2024, Infinity Pharmaceuticals, Inc. shows a mildly bearish trend with daily moving averages indicating weakness, while it has significantly underperformed the S&P 500 over the past decade with a return of -99.99% compared to the S&P's 231.64%.

As of 29 November 2024, the technical trend for Infinity Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are both mildly bullish. However, the absence of signals in the RSI and the sideways Bollinger Bands suggest a lack of momentum. Overall, the current technical stance is mildly bearish. <BR><BR>In terms of returns, the stock has significantly underperformed compared to the S&P 500 over the past three, five, and ten years, with returns of -99.99% versus the S&P's 70.41%, 96.61%, and 231.64%, respectively.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.82

stock-summary
Return on Equity

109.47%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2023)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
-97.3%
0%
-97.3%
3 Years
-99.98%
0%
-99.98%
4 Years
-99.99%
0%
-99.99%
5 Years
-100.0%
0%
-100.0%

Infinity Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Infinity Pharmaceuticals, Inc. technically bullish or bearish?

As of 29 November 2024, the technical trend for Infinity Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are both mildly bullish. However, the absence of signals in the RSI and the sideways Bollinger Bands suggest a lack of momentum. Overall, the current technical stance is mildly bearish. In terms of returns, the stock has significantly underperformed compared to the S&P 500 over the past three, five, and ten years, with returns of -99.99% versus the S&P's 70.41%, 96.61%, and 231.64%, respectively....

Read More

Is Infinity Pharmaceuticals, Inc. overvalued or undervalued?

As of 8 July 2024, the valuation grade for Infinity Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. Based on the available metrics, the company appears to be overvalued given its negative EV to EBIT (-0.73), negative EV to EBITDA (-0.74), and an extremely high ROE of 109.47%, which is misleading due to negative capital employed. In comparison with peers, Avalo Therapeutics, Inc. has a P/E of -2.6865 and an EV to EBITDA of -0.6568, while ABVC BioPharma, Inc. shows a P/E of -20.1140 and an EV to EBITDA of -23.1803, both indicating that Infinity's ratios are not competitive. Furthermore, Infinity's stock has dramatically underperformed against the S&P 500 over the past three years and five years, with returns of -99.99% compared to the S&P 500's 70.41% and 96.61%, respectively, reinforcing the notion that the stock is currently ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-15.60%
EBIT Growth (5y)
-6.70%
EBIT to Interest (avg)
-30.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.81%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
-0.73
EV to EBITDA
-0.74
EV to Capital Employed
-4.59
EV to Sales
11.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
109.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 25 Schemes (13.35%)

Foreign Institutions

Held by 31 Foreign Institutions (5.98%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is -14.29% vs 40.00% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is 9.09% vs -19.57% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.70",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.00",
          "val2": "-11.40",
          "chgp": "12.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.00",
          "val2": "-11.00",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-17,358.50%",
          "val2": "-15,741.50%",
          "chgp": "-161.70%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 36.84% vs 11.76% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 1.99% vs -11.85% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.60",
          "val2": "1.90",
          "chgp": "36.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-44.40",
          "val2": "-44.60",
          "chgp": "0.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.40",
          "val2": "-45.30",
          "chgp": "1.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-17,294.30%",
          "val2": "-24,264.30%",
          "chgp": "697.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQstock-summary
Jun'23
Mar'23
Change(%)
Net Sales
0.60
0.70
-14.29%
Operating Profit (PBDIT) excl Other Income
-10.00
-11.40
12.28%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-10.00
-11.00
9.09%
Operating Profit Margin (Excl OI)
-17,358.50%
-15,741.50%
-161.70%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2023 is -14.29% vs 40.00% in Mar 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2023 is 9.09% vs -19.57% in Mar 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
2.60
1.90
36.84%
Operating Profit (PBDIT) excl Other Income
-44.40
-44.60
0.45%
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-44.40
-45.30
1.99%
Operating Profit Margin (Excl OI)
-17,294.30%
-24,264.30%
697.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 36.84% vs 11.76% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 1.99% vs -11.85% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Infinity Pharmaceuticals, Inc. stock-summary
stock-summary
Infinity Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
Company Coordinates stock-summary
Company Details
1100 Massachusetts Ave Ste 4 , CAMBRIDGE MA : 02138-5241
stock-summary
Tel: 1 617 4531000
stock-summary
http://www.infi.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."